Compare Nutrien Ltd (NTR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Nutrien Ltd trades at $67.7 (market cap $31.60B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.6× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| NTR | REGN | |
|---|---|---|
Market Cap | $31.60B | $83.19B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $812.27 |
52-Week Low | $53.64 | $555.51 |
Enterprise Value | $43.40B | $77.90B |
Dividend Yield | 3.32% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien Ltd. (NTR) trades at $64.42, down 3.51% over 24 hours, with a bearish technical signal. The stock shows mixed earnings, missing Q2 2026 EPS estimates but beating in Q1. Fundamentals include a P/E of 13.04, net income margin of 8.44%, and a dividend of $0.55 per share. Recent news highlights strong potash sales and cost management, though input cost pressures persist.
The outlook is cautiously optimistic, supported by analyst consensus of $76.67 price target and 60.61% buy ratings. Key opportunities include structural gas advantages and agricultural cycle recovery, while risks involve volatile fertilizer demand and margin compression from higher costs.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
